CVS Health CorpCVSDON'T BUYSep 08, 2020Stock price when the opinion was issued
As of Jun 05, 2026. Market Open.
Bought at less than 10x earnings with recent dividend increase is good for share price appreciation. Recent M&A also good for investors. Will continue to own shares. Excellent management team and solid dividend. Weakness is sector creating opportunities to buyout competitors.
Price target was raised today. This peaked in 2020-1 then was hit with a lot of bad news, like doubts over Signify and Oak Street acquisitions. But that negative sentiment has reversed, like their Medicare Advantage stars rating has gone up, and the street sees profitability rising in their pharmacy benefits management system, based on a new model last month. Trades under a cheap PE and pays a 3% dividend. He targets over $100 in 12 months. Is underloved and over-owned.
Healthcare has lagged this year. They run a chain of pharmacies, Aetna health insurance, pharmacy management and recently bought Oak Health. The CEO is doing a great job, and shares are not expensive around 8.5x PE. They took one some debt to bought some companies, but once they integrated them, it will ramp up cash flow.
(Analysts’ price target is $87.45)
WBA He has owned CVS instead in the past. This and WBA have been hit hard in recent years from a lingering concern over pressure on drug prices in the U.S. So, both have expanded into drug distribution, not just drug retail. The multiple that the market will pay for either has compressed. So, he prefers other stocks in this space, like Loblaws (which owns Shoppers Drug Mart) Drug. Traditionally, drug retailing is a stable business, but in the U.S. the pricing issue remains an overhang.